Global Cerebral Palsy Treatment Market - 2023-2030

Cerebral Palsy Treatment The Global Cerebral Palsy Treatment Market size reached USD 3,207.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 4,280.5 million by 2030. The global cerebral palsy treatment market is expected to exhibit a CAGR of 3.7% during the forecast period 2024-2031.

The growing awareness about cerebral palsy is one of the major factors that would drive the cerebral palsy treatment market growth throughout the forecast period.

For instance, in October 2022, Techwave, a top international IT and engineering solutions provider, shared its recent fundraising endeavor, the “STEPtember, Health & Fitness Challenge.” The movement is being launched in cooperation with the Cerebral Palsy Alliance Research Foundation to raise awareness and funds for families impacted by cerebral palsy.

For instance, in March 2023, The United Cerebral Palsy Research Initiative for the second year began receiving grant applications for awards of up to D 20,000 on National Cerebral Palsy Awareness Day, March 25, for translational studies addressing premature diagnosis and treatment of cerebral palsy and related neurodevelopmental disabilities.

Cerebral Palsy (CP) is a group of disorders caused by abnormal brain development or brain damage that impairs a person's ability to control individual muscles. It affects a person's ability to move, balance and maintain posture and is the most common motor disability found in childhood.

The availability of advanced treatment options for CP is driving the market growth. These include physical therapy, occupational therapy, recreational therapy, surgery and medications. Technological advancements such as FES, virtual reality, stem cell therapy and robotics have already hit the market, while others are still in development or trial stages.

Cerebral Palsy Treatment Market Dynamics and Trends

The Rising Healthcare Expenditure in Cerebral Palsy Treatment is Boosting the Global Cerebral Palsy Treatment Market Growth.

The rising healthcare expenditure in cerebral palsy treatment refers to the increasing amount of money that is being spent on medical care, research and development related to cerebral palsy. In developed countries, healthcare expenditure on cerebral palsy treatment is driven by the high cost of medical care and the need for specialized equipment and facilities.

In the U.S., the annual cost of medical care for a child with cerebral palsy can range from D 50,000 to D 150,000, including hospitalization, medication, therapy and assistive devices.

Moreover, Governments and NGOs are working by investing in healthcare infrastructure and facilities, as well as increasing awareness about cerebral palsy. Hence, owing to the above factors, the market is expected to drive over the forecast period.

The Limited Availability of Specialized Care is Hampering the Growth of the Global Cerebral Palsy Treatment Market.

Cerebral palsy is a complex condition that requires a multidisciplinary team of healthcare professionals. However, the expertise required for diagnosis and treatment may be limited in some regions, making it difficult for patients to access specialized care. This is a major restraint on the growth of the cerebral palsy treatment market.

For instance, the concentration of expertise in urban areas can lead to limited access to specialized care for patients living in rural or remote areas, while in developing countries, there may be a shortage of healthcare professionals with the expertise required for cerebral palsy treatment, leading to delayed diagnosis and treatment. Thus, from the above factors, the global cerebral palsy treatment market is expected to be hampered over the forecast period.

Cerebral Palsy Treatment Market Segment Analysis

The global cerebral palsy treatment market is segmented based on drug type, disease type, distribution channel and region.

The Anticonvulsant Segment is Expected to Hold a Dominant Position in the Market over the Forecast Period.

The anticonvulsant segment accounted for the highest market stake accounting for approximately 48.0% of the cerebral palsy treatment market in 2022. Anticonvulsants are used to reduce or avoid seizure activity, stabilize mood and depress brain activity without affecting breathing or sleepiness. The medical expert selects a drug and dose that is appropriate for the kind of seizure the child is experiencing and monitors the child for any adverse effects that may necessitate a prescription or dose revision.

For instance, the common anticonvulsants include Gabapentin (Neurontin), Lamotrigine (Lamictal), Oxcarbazepine (Trileptal), Topiramate (Topamax) and Zonisamide (Zonegran) among others. Moreover, the increasing number of clinical trials by the research instituted is the other factor expected to boost the anticonvulsant segment over the forecast period.

For instance, on January 20, 2023, Zagazig University conducted a Phase II interventional study of the Neuroprotective Impact of Magnesium Sulphate Therapy for Preterm Deliveries. The study is expected to be completed by July 15, 2024.

Cerebral Palsy Treatment Market Geographical Share

North America Holds a Dominant Position in the Global Cerebral Palsy Treatment Market.

North America is estimated to hold around 40.3% of the total cerebral palsy treatment market share throughout the forecast period, owing to the introduction of the cerebral palsy research program act and increasing awareness about cerebral palsy.

For instance, in March 2022, the Cerebral Palsy Research Program Act, introduced by Congressman Steve Cohen and co-sponsored by Representatives Brian Fitzpatrick and Emanuel Cleaver, established a cerebral palsy research program within the CDC and provided the first-ever dedicated source of federal funding for cerebral palsy research.

Hence, owing to the above factors, the cerebral palsy treatment market is expected to boost in the North American region over the forecast period.

Cerebral Palsy Treatment Companies

The major global players in the market include Merz Pharmaceuticals, LLC., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical and Hikma Pharmaceuticals Plc among others.

COVID-19 Impact on Cerebral Palsy Treatment Market

Russia-Ukraine Conflict Analysis

The invasion of Ukraine by Russia has caused a severe humanitarian crisis, with a devastating impact on people living with intellectual disabilities and their families. The community was suffering from a chronic shortage of support services before the invasion began and with resources diverted to the war effort, the few that did exist are struggling to cope.

Children in orphanages with disabilities had become twisted and constricted due to a lack of activity and treatment for spastic cerebral palsy. During the war, charitable organizations provided children with cerebral palsy with regular treatments to reduce pain.

However, their access to care will diminish as war grips the country. The charitable organizations provided them with the means to access essential medical care. Therefore, the conflict has had a moderate impact on the global cerebral palsy treatment market.

Artificial Intelligence Impact Analysis

Artificial intelligence is expected to impact the global cerebral treatment market positively.AI applications can benefit children with CP through symptom management devices, such as mobile devices that adapt to the terrain and avoid obstacles. These devices are ideal for wheelchair users.

Moreover, research has found that AI systems are being used to support therapy for children with cerebral palsy, assessing their movement and making therapy more fun. Similarly, AI algorithms can be used to make therapy more fun and engaging, such as virtual reality, which can help children with cerebral palsy improve motor function more quickly.

Key Developments
• On May 23, 2022, Teva Pharmaceutical Industries Ltd. released new efficacy and safety results from a three-year open-label extension (OLE) investigation involving AUSTEDO (deutetrabenazine) tablets among postmenopausal women having tardive dyskinesia.
• On February 17, 2023, the U.S. FDA approved Teva Pharmaceutical Industries Ltd. AUSTEDOXR tablets, a novel once-daily formulation for tardive dyskinesia and chorea linked to Huntington's disease. AUSTEDO XR is an extra formulation of the twice-daily medication.
• On March 24, 2022, Hikma Pharmaceuticals USA Inc. released Benztropine Mesylate Injection, USP in a vial-formatted 2mg/2mL dosage.

Why Purchase the Report?
• To visualize the global cerebral palsy treatment market segmentation based on the drug type, disease type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cerebral palsy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Cerebral Palsy Treatment Market Report Would Provide Approximately 61 Tables, 54 Figures and 195 Pages.

Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies